{"id":"gp2015","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Bone pain"},{"rate":"5-10","effect":"Injection site reactions"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":"5-10","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GP2015 is designed as a biosimilar to pegfilgrastim, a pegylated recombinant human granulocyte colony-stimulating factor (G-CSF). It binds to G-CSF receptors on hematopoietic progenitor cells in the bone marrow, promoting their proliferation, differentiation, and activation into mature neutrophils. This mechanism helps reduce the incidence of chemotherapy-induced neutropenia and its complications in cancer patients receiving myelosuppressive chemotherapy.","oneSentence":"GP2015 is a biosimilar of pegfilgrastim that stimulates neutrophil production by binding to G-CSF receptors on bone marrow progenitor cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:16.155Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Reduction of the duration of neutropenia and the incidence of febrile neutropenia in patients receiving myelosuppressive chemotherapy for malignancy"}]},"trialDetails":[{"nctId":"NCT02638259","phase":"PHASE3","title":"Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sandoz","startDate":"2015-02-21","conditions":"Rheumatoid Arthritis","enrollment":376},{"nctId":"NCT01891864","phase":"PHASE3","title":"Study to Demonstrate Equivalent Efficacy and to Compare Safety of Biosimilar Etanercept (GP2015) and Enbrel","status":"COMPLETED","sponsor":"Sandoz","startDate":"2013-06","conditions":"Chronic Stable Plaque Psoriasis","enrollment":531}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ARTHRALGIA"},{"count":1,"reaction":"C-REACTIVE PROTEIN INCREASED"},{"count":1,"reaction":"NASOPHARYNGITIS"},{"count":1,"reaction":"PNEUMONIA"},{"count":1,"reaction":"TIBIA FRACTURE"},{"count":1,"reaction":"WHITE BLOOD CELL COUNT INCREASED"}],"_approvalHistory":[],"publicationCount":23,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"GP2015","genericName":"GP2015","companyName":"Sandoz","companyId":"sandoz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GP2015 is a biosimilar of pegfilgrastim that stimulates neutrophil production by binding to G-CSF receptors on bone marrow progenitor cells. Used for Reduction of the duration of neutropenia and the incidence of febrile neutropenia in patients receiving myelosuppressive chemotherapy for malignancy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}